Superworth

Cryoport price to book ratio CYRX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
1.9×
10-year median
4.2×
Against its 10-year history
38th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.7× to 27.1×
Peer median
2.5×

Cryoport's price to book ratio is 1.9× as of Oct 23, 2026.

That is below its ten-year median of 4.2×, close to the middle of its last ten years.

Over that time it ranged from 0.7× in Feb 2025 to 27.1× in Jan 2021.

The median for 10 large drugmakers of a similar size is 2.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.9×0.8×1.9×
20250.9×0.7×1.0×
20240.9×0.7×1.8×
20231.4×0.8×2.2×
20221.5×1.4×3.8×
20214.2×3.5×27.1×
202014.5×4.3×19.5×
20195.3×4.6×18.2×
20189.8×9.1×19.9×
201712.4×4.0×17.8×
201615.4×1.5×16.2×
20152.2×2.2×11.0×
2014n/m a value too high to mean anything
201326.7×17.0×26.7×
201216.0×3.0×36.0×
20117.7×6.0×10.0×

Against its peers

Companies in Drug Manufacturers - General nearest Cryoport's size, closest first, today.

CompanyPrice to book ratio
CYRXCryoport1.9×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
COLLCollegium Pharmaceutical2.4×
OMEROmerosn/m
CRMDCorMedix1.3×
ZVRAZevra Therapeutics2.7×
IRWDIronwood Pharmaceuticalsn/m
PCRXPacira BioSciences2.2×
ANABAnaptysbio138×
PBYIPuma Biotechnology4.1×
Peer median2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Cryoport

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.